Position in MYGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$332,914
-$198,906 QoQ
Shares Held
73,981
-14.4% QoQ
Ownership
0.078%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 2%
Shared 30%
None 68%
Common Shares in MYGN Over Time
Shares Held
Position Value (USD)
Position in Diagnostics & Research
Healthcare · as of Mar 31, 2026Cerity Partners LLC holds $380,283,670 across 28 Diagnostics & Research names. MYGN ranks #22 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TMO |
Thermo Fisher Scientific Inc.
|
200,486 | $98,544,882 | |
| 2 | DHR |
Danaher Corp /De/
|
396,584 | $75,192,325 | |
| 3 | MEDP |
Medpace Holdings, Inc.
|
82,077 | $39,412,553 | |
| 4 | IQV |
Iqvia Holdings Inc.
|
144,059 | $24,567,821 | |
| 5 | LH |
Labcorp Holdings Inc.
|
85,079 | $22,699,927 | |
| 6 | NTRA |
Natera, Inc.
|
109,716 | $21,942,102 | |
| 7 | ILMN |
Illumina, Inc.
|
171,766 | $21,171,876 | |
| 8 | A |
Agilent Technologies, Inc.
|
154,346 | $17,592,355 |
All Filings in MYGN
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $332,914 | 73,981 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $531,820 | 86,475 | Shares | Sole | 2026-02-11 | |
| 2025-09-30 | $575,160 | 79,552 | Shares | Other | 2025-10-22 | |
| 2025-06-30 | $119,108 | 22,431 | Shares | Defined | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||